20/20 Biolabs Inc (NASDAQ:AIDX) Sees Significant Increase in Short Interest

20/20 Biolabs Inc (NASDAQ:AIDX) was the recipient of a significant increase in short interest in April. As of April 30th, there was short interest totaling 33,116 shares, an increase of 74.8% from the April 15th total of 18,940 shares. Based on an average daily volume of 61,031 shares, the short-interest ratio is presently 0.5 days. Currently, 0.3% of the shares of the stock are sold short.

20/20 Biolabs Stock Performance

NASDAQ AIDX opened at $1.34 on Wednesday. 20/20 Biolabs has a twelve month low of $1.26 and a twelve month high of $50.00. The business’s 50 day moving average price is $1.80.

20/20 Biolabs (NASDAQ:AIDX) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($0.26) EPS for the quarter. The firm had revenue of $0.54 million for the quarter.

Analyst Ratings Changes

Several equities research analysts recently commented on AIDX shares. Maxim Group started coverage on 20/20 Biolabs in a report on Monday, May 11th. They set a “buy” rating and a $5.00 target price on the stock. Weiss Ratings started coverage on 20/20 Biolabs in a report on Thursday, May 14th. They set a “sell (e-)” rating on the stock. Finally, Wall Street Zen raised 20/20 Biolabs to a “hold” rating in a report on Saturday, March 14th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $5.00.

20/20 Biolabs Company Profile

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.